دورية أكاديمية
أعرض في EDS

High efficacy of artemether-lumefantrine and declining efficacy of artesunate + sulfadoxine-pyrimethamine against Plasmodium falciparum in Sudan (2010-2015): evidence from in vivo and molecular marker studies.

التفاصيل البيبلوغرافية
العنوان: High efficacy of artemether-lumefantrine and declining efficacy of artesunate + sulfadoxine-pyrimethamine against Plasmodium falciparum in Sudan (2010-2015): evidence from in vivo and molecular marker studies.
المؤلفون: Adeel AA; College of Medicine, King Saud University, Riyadh, Saudi Arabia. aaadeel@yahoo.com., Elnour FA; National Malaria Control Programme, Federal Ministry of Health, Khartoum, Sudan., Elmardi KA; National Malaria Control Programme, Federal Ministry of Health, Khartoum, Sudan., Abd-Elmajid MB; National Malaria Control Programme, Federal Ministry of Health, Khartoum, Sudan., Elhelo MM; National Malaria Control Programme, Federal Ministry of Health, Khartoum, Sudan., Ali MS; National Malaria Control Programme, Federal Ministry of Health, Khartoum, Sudan., Adam MA; National Malaria Control Programme, Federal Ministry of Health, Khartoum, Sudan., Atta H; Malaria Control and Elimination, Division of Communicable Diseases Control, World Health Organization Regional Office for the Eastern Mediterranean, Cairo, Egypt., Zamani G; Malaria Control and Elimination, Division of Communicable Diseases Control, World Health Organization Regional Office for the Eastern Mediterranean, Cairo, Egypt., Warsame M; Global Malaria Programme, World Health Organization, Geneva, Switzerland., Barrette A; Global Malaria Programme, World Health Organization, Geneva, Switzerland., Mohammady HE; Naval Medical Research Unit-3, Cairo, Egypt., Nada RA; Naval Medical Research Unit-3, Cairo, Egypt.
المصدر: Malaria journal [Malar J] 2016 May 21; Vol. 15 (1), pp. 285. Date of Electronic Publication: 2016 May 21.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101139802 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2875 (Electronic) Linking ISSN: 14752875 NLM ISO Abbreviation: Malar J Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, [2002-
مواضيع طبية MeSH: Drug Resistance*, Antimalarials/*therapeutic use , Artemisinins/*therapeutic use , Ethanolamines/*therapeutic use , Fluorenes/*therapeutic use , Malaria, Falciparum/*drug therapy , Plasmodium falciparum/*drug effects , Pyrimethamine/*therapeutic use , Sulfadoxine/*therapeutic use, Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antimalarials/pharmacology ; Artemether, Lumefantrine Drug Combination ; Artemisinins/pharmacology ; Artesunate ; Child ; Child, Preschool ; Dihydropteroate Synthase/genetics ; Drug Combinations ; Ethanolamines/pharmacology ; Female ; Fluorenes/pharmacology ; Genetic Markers ; Genotype ; Humans ; Infant ; Infant, Newborn ; Malaria, Falciparum/parasitology ; Male ; Middle Aged ; Plasmodium falciparum/genetics ; Plasmodium falciparum/isolation & purification ; Pyrimethamine/pharmacology ; Sudan ; Sulfadoxine/pharmacology ; Tetrahydrofolate Dehydrogenase/genetics ; Treatment Outcome ; Young Adult
مستخلص: Background: The present paper reports on studies that evaluated artesunate + sulfadoxine-pyrimethamine (AS + SP) which is the first-line drug and artemether-lumefantrine (AL) which is a second-line drug against uncomplicated falciparum malaria in Sudan. This evaluation was performed in twenty studies covering six sentinel sites during five successive annual malaria transmission seasons from 2010 to 2015.
Methods: The standard World Health Organization protocol was used for a follow-up period of 28 days. The frequency distribution of molecular markers for antifolate resistance in dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) genes was studied in pre-treatment samples in four sites in 2011.
Results: In the nine studies of AL conducted at five sites (n = 595), high PCR-corrected cure rates were found, ranging from 96.8 to 100 %. Among the eleven studies of AS + SP (n = 1013), a decline in the PCR-corrected cure rates was observed in Gedaref in Eastern Sudan: 91.0 % in the 2011-12 season and 86.5 % in the 2014-15 season. In the remaining sites, the AS + SP cure rates ranged between 95.6 and 100 %. The rate of clearance of microscopic gametocytaemia after treatment was not significantly different with AL or AS + SP on days 7, 14, 21 and 28 of follow-up. A total of 371 pre-treatment samples were analysed for molecular markers of SP resistance. The temporal changes and geographical differences in the frequency distribution of SP-resistance genotypes showed evidence of regional differentiation and selection of resistant strains.
Conclusion: The findings of this study call for a need to review the Sudan malaria treatment policy. Epidemiological factors could play a major role in the emergence of drug-resistant malaria in eastern Sudan.
Australian New Zealand Clinical Trials Registry: Trial registration numbers 2011-2012: ACTRN12611001253998, 2013-2015: ACTRN12613000945729.
References: Trans R Soc Trop Med Hyg. 1998 Nov-Dec;92(6):589-92. (PMID: 10326097)
Philos Trans R Soc Lond B Biol Sci. 1999 Apr 29;354(1384):739-49. (PMID: 10365399)
Antimicrob Agents Chemother. 2000 Mar;44(3):697-704. (PMID: 10681341)
Antimicrob Agents Chemother. 2000 Apr;44(4):991-6. (PMID: 10722502)
Am J Trop Med Hyg. 2000 Mar;62(3):396-401. (PMID: 11037785)
J Infect Dis. 2002 Feb 1;185(3):380-8. (PMID: 11807721)
East Mediterr Health J. 2000 Sep-Nov;6(5-6):939-47. (PMID: 12197352)
J Infect Dis. 2003 Jun 15;187(12):1870-5. (PMID: 12792863)
Afr J Med Med Sci. 2001;30 Suppl:43-6. (PMID: 14513938)
Am J Trop Med Hyg. 2003 Nov;69(5):558-63. (PMID: 14695097)
J Infect Dis. 2004 Apr 1;189(7):1239-44. (PMID: 15031793)
Science. 2004 Aug 20;305(5687):1124. (PMID: 15326348)
Drug Resist Updat. 2004 Aug-Oct;7(4-5):279-88. (PMID: 15533765)
J Pharm Pharm Sci. 2005 Aug 12;8(2):326-31. (PMID: 16124943)
East Afr Med J. 2005 Aug;82(8):391-5. (PMID: 16261914)
Trop Med Int Health. 2006 May;11(5):604-12. (PMID: 16640612)
Infect Genet Evol. 2007 Jan;7(1):52-9. (PMID: 16690361)
Malar J. 2006 Jul 31;5:65. (PMID: 16879742)
Malar J. 2006 Nov 24;5:113. (PMID: 17125496)
Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):153-9. (PMID: 18165488)
Trends Parasitol. 2008 Mar;24(3):127-34. (PMID: 18262470)
Eur J Clin Microbiol Infect Dis. 2008 Aug;27(8):725-32. (PMID: 18373107)
PLoS Med. 2009 Apr 14;6(4):e1000055. (PMID: 19365539)
Infect Genet Evol. 2009 Sep;9(5):778-83. (PMID: 19379843)
N Engl J Med. 2009 Jul 30;361(5):455-67. (PMID: 19641202)
Am J Trop Med Hyg. 2010 Aug;83(2):250-7. (PMID: 20682863)
Malar J. 2010 Aug 30;9:247. (PMID: 20799995)
Malar J. 2011 Aug 02;10:214. (PMID: 21810256)
Afr Health Sci. 2011 Jun;11(2):142-50. (PMID: 21857842)
Am J Trop Med Hyg. 2011 Nov;85(5):793-804. (PMID: 22049029)
Infect Genet Evol. 2012 Aug;12(6):1253-9. (PMID: 22709478)
Malar J. 2013 Jul 19;12:255. (PMID: 23870667)
Trends Parasitol. 2013 Oct;29(10):505-15. (PMID: 24028889)
Acta Trop. 2013 Dec;128(3):636-41. (PMID: 24055717)
Malar J. 2014 Jul 28;13:291. (PMID: 25069530)
Acta Trop. 1989 May;46(3):157-65. (PMID: 2566268)
Malar J. 2015 Nov 14;14:449. (PMID: 26573814)
Trans R Soc Trop Med Hyg. 1989 Jul-Aug;83(4):486-7. (PMID: 2694486)
Sudan J Paediatr. 2012;12(1):8-20. (PMID: 27493325)
Proc Natl Acad Sci U S A. 1988 Dec;85(23):9109-13. (PMID: 3057499)
Am J Trop Med Hyg. 1972 Sep;21(5):736-43. (PMID: 4561521)
Am J Trop Med Hyg. 1995 Jun;52(6):565-8. (PMID: 7611566)
Trans R Soc Trop Med Hyg. 1993 Jan-Feb;87(1):75-8. (PMID: 8465404)
Lancet. 1996 Jun 15;347(9016):1654-8. (PMID: 8642959)
Trans R Soc Trop Med Hyg. 1996 Mar-Apr;90(2):181-2. (PMID: 8761584)
Am J Trop Med Hyg. 1996 Aug;55(2):209-13. (PMID: 8780462)
Antimicrob Agents Chemother. 1998 Jul;42(7):1811-4. (PMID: 9661026)
Ann Trop Med Parasitol. 1998 Jun;92(4):449-58. (PMID: 9683896)
معلومات مُعتمدة: 001 International WHO_ World Health Organization
فهرسة مساهمة: Keywords: Artemether-lumefantrine antimalarial drugs; Artesunate; Drug resistance; Molecular markers; Sudan; Sulfadoxine-pyrimethamine; dhfr; dhps
سلسلة جزيئية: ANZCTR ACTRN12611001253998; ACTRN12613000945729
المشرفين على المادة: 0 (Antimalarials)
0 (Artemether, Lumefantrine Drug Combination)
0 (Artemisinins)
0 (Drug Combinations)
0 (Ethanolamines)
0 (Fluorenes)
0 (Genetic Markers)
37338-39-9 (fanasil, pyrimethamine drug combination)
60W3249T9M (Artesunate)
88463U4SM5 (Sulfadoxine)
EC 1.5.1.3 (Tetrahydrofolate Dehydrogenase)
EC 2.5.1.15 (Dihydropteroate Synthase)
Z3614QOX8W (Pyrimethamine)
تواريخ الأحداث: Date Created: 20160523 Date Completed: 20170628 Latest Revision: 20220129
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC4875683
DOI: 10.1186/s12936-016-1339-x
PMID: 27209063
قاعدة البيانات: MEDLINE
الوصف
تدمد:1475-2875
DOI:10.1186/s12936-016-1339-x